Regeneron Pharmaceuticals, Inc. $REGN Stock: Park Avenue Securities LLC Raises Stake

Park Avenue Securities LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 79.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,809 shares of the biopharmaceutical company’s stock after purchasing an additional 1,246 shares during the quarter. Park Avenue Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $2,130,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of REGN. Orbimed Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $11,358,000. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $5,682,636,000. Contravisory Investment Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $6,327,000. Oxbow Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $3,342,000. Finally, Deutsche Bank AG acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $323,249,000. 83.31% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Andrew Murphy sold 4,147 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the sale, the insider directly owned 47,833 shares in the company, valued at $36,960,559.10. This trade represents a 7.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the sale, the executive vice president directly owned 13,134 shares in the company, valued at $11,163,900. This represents a 8.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock worth $6,506,845 over the last three months. Corporate insiders own 6.97% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $927.89 on Friday. The firm has a market capitalization of $95.54 billion, a price-to-earnings ratio of 20.49, a price-to-earnings-growth ratio of 1.57 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The business has a fifty day moving average of $793.30 and a 200 day moving average of $738.05. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $935.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm’s revenue was up 36.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.83 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. TD Cowen increased their price target on Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Raymond James Financial boosted their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Finally, Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $850.83.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.